Loading
DNA and Nucleic Acid Chemistry · Journal article
Small · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a proof-of-concept preclinical study demonstrating that a novel modularized DNA nanostructure (AS1411-DNT) loaded with 5-fluorouracil shows superior therapeutic efficacy compared to free drug in a mouse xenograft model. The work is early-stage, lacks standardized comparators and detailed statistical reporting, and does not establish safety or efficacy profiles required for clinical translation.
Single-arm preclinical in vivo efficacy study in tumor-bearing mice. MCF-7 tumor-bearing mouse models (breast cancer xenograft); specific age, sex, and number of animals not stated.. Intervention: AS1411-DNT-5-FU: modularized DNA nanotube conjugate with aptamer AS1411 and embedded 5-fluorouracil. Compared with: Free 5-FU (clinical standard reference).
AS1411-DNT exhibits nuclease degradation resistance improved by approximately 92-fold compared with Biotin-DNA nanowire DNA nanotube dimensions: circumference 118.6 nm, length 478 nm, with assembly efficiency of almost 90% AS1411-DNT-5-FU conjugate shows significantly higher therapeutic outcomes than free 5-FU in MCF-7 tumor-bearing mice without observable systemic toxicity
Systemic toxicity is described only as 'not observable' without pharmacokinetics, biodistribution, or organ pathology data AS1411-DNT-5-FU conjugate shows significantly higher therapeutic outcomes than free 5-FU in MCF-7 tumor-bearing mice without observable systemic toxicity
This work addresses drug delivery strategy in principle but is far from clinical application. Clinicians should view this as early nanotechnology development; no patient-relevant outcomes are reported, and toxicity assessment is limited to a single observation of lack of 'observable' systemic toxicity without quantitative data.
Early-stage preclinical work demonstrating proof-of-concept for a novel DNA nanostructure in a single mouse tumor model, lacking controlled comparators, toxicity data, and mechanistic validation needed for clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This work addresses drug delivery strategy in principle but is far from clinical application. Clinicians should view this as early nanotechnology development; no patient-relevant outcomes are reported, and toxicity assessment is limited to a single observation of lack of 'observable' systemic toxicity without quantitative data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
While DNA origami nanotubes have been often used in the biomedical field, the technical challenges in the assembly at large scale and the susceptibility to degradation limit their exploration for clinical application. In the current contribution, we propose a structural DNA nanotechnology (TMM) for the construction of a degradation-resistant DNA nanotube (DNT) via periodically tiling two structural modules (M) into a modularized (M) tubular DNA nano-architecture. The tube circumference is 118.6 nm, the tube length is 478 nm and the assembly efficiency is almost up to 90%. Upon installation of up-down tumor cell-binding aptamers onto each structural module in a highly precise manner, a protective outer layer was formed. Compared with Biotin-DNA nanowire, the relative nuclease degradation resistance of AS1411-DNT is improved by about 92-fold. Via using commercially synthesized 5-FU-embedded DNA components, we constructed a tumor cell-targeting therapeutic agent-loaded nanoconjugate, AS1411-DNT-5-FU, which exhibits significantly higher therapeutic outcomes than clinic free 5-FU in MCF-7 tumor-bearing mouse models without observable systemic toxicity. While DNA DNT holds great potential for precise drug delivery for cancer therapy, the modularization-based TMM structural DNA nanotechnology is expected to promote the development of next-generation multifunctional 3D-DNA nanostructures and clinical application in precision medicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.